Event in Progress:
Discover the latest content that has just been published on Research Tree
Qiagen’s Q3 results were largely in-line with expectations. A significant decline in the COVID-19 product offerings overshadowed the growth in the routine testing business. More importantly, the 2023 guidance was reiterated. Overall, considering that non-COVID-19 testing market opportunities are here to stay (also acknowledged by the other testing giants), along with the firm’s sustained focus on its five pillars of growth and healthy balance sheet, our positive recommendation is reaffirmed.
Companies: QIAGEN NV (QGEN:NYSE)QIAGEN NV (QGEN:NYS)
AlphaValue
Qiagen reported soft Q2 results, as a severe decline in COVID-19 sales overshadowed the high-single-digit growth for the non-COVID-19 product group. More importantly, the guidance was downgraded which also incorporates the unpredictability in bulk orders in the OEM business. Overall, considering the resilient demand for routine testing, along with continuous innovation and balance sheet strength, we reiterate our positive recommendation.
Qiagen reported mixed Q1 results. Double-digit growth in the non-COVID-19 product group was, however, offset by the significant decline in COVID-19 sales. Notably, 2023 guidance was maintained, suggesting healthy dynamics for its non-COVID-19 product portfolio. Overall, considering non-COVID-19 testing tailwinds will continue along with the firm’s healthy measures in expanding the scope of offerings and bolt-on initiatives, our positive stock recommendation is maintained.
Qiagen reported better-than-expected Q4 results. Double-digit growth in the non-Covid-19 product group was however overshadowed by the substantial decline in Covid-19 sales. Moreover, the 2023 guidance assumes a further material decline in Covid-19 sales. However, with the lynchpin segment, i.e. non-Covid-19 products, again guided to clock healthy double-digit growth in 2023, and various innovation and bolt-on initiatives, Qiagen remains an attractive sector bet – which may also garner new M&A i
Qiagen’s Q3 22 results came in ahead of the company-compiled consensus estimates. While COVID-19 testing sales moderation continued (also a sector-wide trend), non-COVID-19 robust growth momentum resulted in a third guidance upgrade in a row. Considering that non-COVID-19 testing tailwinds will continue along with the firm’s strategic initiatives of expanding the scope of offerings, and the re-emerging M&A rumours, our positive stock recommendation is reiterated.
Research Tree provides access to ongoing research coverage, media content and regulatory news on QIAGEN NV. We currently have 46 research reports from 3 professional analysts.
Companies: Warpaint London PLC
Shore Capital
Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol
Companies: NBPE ICGT ARBB RECI CLIG HAT AVO VTA APAX
Hardman & Co
Avon Protection’s capital markets day highlighted its continued focus on medium-term margin expansion (targeting operating margin of 14–16%), concentrating on its core business of respirators and head protection. The unwinding of the armour business, alongside the consolidation of Team Wendy (acquired in H220) should enable Avon to benefit from rising global defence spending. Its strong relationship with the US DoD, and organic growth opportunities with recurring revenue from necessary product r
Companies: Avon Protection PLC
Edison
Companies: SCE HVO VLG
Cavendish
15th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated propositio
Companies: GTC SAV FAB KRM BOOM
Hybridan
Companies: IGP RUA BOOM
17th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: ARS TIDE SCE SNX ECK CNS TST SPEC SSTY
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. Further growth in 202
Companies: Tissue Regenix Group plc
Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We
Companies: Cambridge Nutritional Sciences PLC
Companies: BILN IGP RBN SBTX
Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x. Management have focused on growth with three therapy areas generating double-digit revenue growth and onli
Companies: Venture Life Group Plc
Creo Medical has released a trading update for FY23, an active year for the company, with progress made across all business segments. Traction improved in H223, following Speedboat Inject’s European clearance for upper gastrointestinal (GI) procedures and the accelerated approval and launch of Creo’s slimmest electrosurgical device, Speedboat UltraSlim. Top-line growth was supported by continued streamlining of the cost structure, resulting in a better-than-expected underlying EBITDA loss (impro
Companies: Creo Medical Group Plc
Zoetis delivered a decent set of results for the last quarter of 2022 meeting analyst expectations as well as the high end of its management guidance. Despite the economic challenges, ongoing pandemic recovery, and the political unpredictability brought on by the war in Ukraine, they delivered operational growth for the year in each of their top 13 markets. The company's unique companion animal portfolio drove its 8% operational revenue increase for the year, growing 14% operationally. In compar
Companies: Zoetis (ZTS:NYSE)Zoetis, Inc. Class A (ZTS:NYS)
Baptista Research
Share: